Mast Therapeutics, Inc. (SVRA) Downgraded by Zacks Investment Research
Mast Therapeutics, Inc. (NASDAQ:SVRA) was downgraded by Zacks Investment Research from a “buy” rating to a “hold” rating in a report released on Friday.
According to Zacks, “Savara Inc. is a clinical-stage pharmaceutical company. It focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Savara Inc., formerly known as Mast Therapeutics, Inc., is based in Austin, United States. “
SVRA has been the topic of several other reports. Canaccord Genuity started coverage on shares of Mast Therapeutics in a report on Wednesday, June 7th. They issued a “buy” rating and a $18.00 price target on the stock. JMP Securities started coverage on shares of Mast Therapeutics in a report on Monday. They issued an “outperform” rating and a $20.00 price target on the stock.
Mast Therapeutics (SVRA) opened at 9.39 on Friday. The company’s market capitalization is $227.19 million. Mast Therapeutics has a 52-week low of $4.60 and a 52-week high of $45.35. The company has a 50-day moving average price of $5.96 and a 200 day moving average price of $5.97.
TRADEMARK VIOLATION NOTICE: “Mast Therapeutics, Inc. (SVRA) Downgraded by Zacks Investment Research” was posted by American Banking News and is owned by of American Banking News. If you are viewing this story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The correct version of this story can be read at https://www.americanbankingnews.com/2017/09/15/mast-therapeutics-inc-svra-downgraded-by-zacks-investment-research.html.
About Mast Therapeutics
Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Mast Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mast Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.